Arrowhead Research (ARWR) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Cuts Price Target on Arrowhead Research (ARWR) to $8.00 Following 3Q
August 10, 2016 8:53 AM EDTPiper Jaffray maintained an Overweight rating on Arrowhead Research (NASDAQ: ARWR), and cut the price target to $8.00 (from $13.00), following the company's 3Q earnings report. Arrowhead ended FY3Q:16 with cash of $44.6 million and issued 7.63 million shares at $5.90 per share bringing proforma cash to ~$90 million.... More
Arrowhead Research (ARWR) Prices $45M Private Stock Offering at $5.90/Share
August 9, 2016 9:06 AM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million. The offering was priced at $5.90 per share.
Cantor Fitzgerald & Co. acted as sole placement agent for the offering.
Approximately 7.63 million... More
